Glenmark Pharmaceuticals (GLENMARK) Share Price Falls 2.56% Today

Glenmark Pharmaceuticals Share Price fell to Rs 2,414 on 09 September 2026 at 10:53:16 AM IST, down 2.56% or Rs 63.35 for the session so far. The company remained in the Large Cap category, with a market capitalisation of Rs 69,483.71 crore. The session also showed a notable intraday reversal: the stock opened at Rs 2,486.9, which was also the day’s high, and later moved down to a low of Rs 2,403.1.

The supplied market data confirms the decline but does not identify a company-specific trigger. Even without a stated catalyst, the move is relevant because Glenmark is a sizeable healthcare name in the Pharmaceuticals & Drugs industry. That means today’s weakness is best assessed not only through price action, but also through valuation, profitability and peer positioning within the listed pharma space.

Glenmark Pharmaceuticals (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,414
Previous Close	Rs 2,477.35
Today's Move	-Rs 63.35 (-2.56%)
Open	Rs 2,486.9
High	Rs 2,486.9
Low	Rs 2,403.1
Turnover	Rs 1.41 crore
Market Capitalisation	Rs 69,483.71 crore
Market Cap Category	Large Cap

The intraday structure was clearly weak. The stock opened at the top of the day’s range and failed to hold that level, with the high and opening price both at Rs 2,486.9. From there, it slipped to Rs 2,403.1 before trading at Rs 2,414 at the captured timestamp. That pattern usually indicates early selling pressure after the open, although the data does not attribute the move to any specific announcement.

Turnover stood at Rs 1.41 crore when the snapshot was recorded. For traders, the main reference points from the session are the gap between the previous close of Rs 2,477.35 and the current price, plus the fact that the stock stayed below the opening mark. For longer-term followers, today’s price move matters because it comes in a large listed pharma company whose valuation and returns already attract comparison with sector benchmarks.

Glenmark Pharmaceuticals (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 69,483.71 crore
P/E Ratio	38.89x
P/B Ratio	6.38x
ROE	14.1%
ROCE	20.35%
EPS	Rs 63.7
Book Value Per Share	Rs 388.43
Dividend Yield	0.1%

From a fundamentals standpoint, the company combines meaningful scale with healthy return ratios. It trades at a P/E of 38.89 and a P/B of 6.38, while ROE stands at 14.1% and ROCE at 20.35%. EPS is Rs 63.7, book value per share is Rs 388.43 and dividend yield is 0.1%.

Those figures suggest a profitable business, but not a cheaply valued one. A market cap of Rs 69,483.71 crore places Glenmark among the bigger listed pharma names, and its return profile is stronger than many industry reference points. At the same time, the valuation multiples indicate that investors are paying above-median sector prices for those returns. That combination is important when a stock falls, because market participants often judge whether the price move is changing the valuation story or simply adjusting a premium name within its usual range.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	38.89x
Benchmark Median P/E	32.19x
Benchmark Average P/E	49.13x
Benchmark P/E Range	3.39x to 668.68x
Company P/B Ratio	6.38x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.44x
Company ROE	14.1%
Benchmark Median ROE	11.82%
Benchmark Average ROE	11.12%
Company ROCE	20.35%
Benchmark Median ROCE	13.71%
Benchmark Average ROCE	13.62%
Company Market Capitalisation	Rs 69,483.71 crore
Benchmark Median Market Cap	Rs 715.6 crore
Benchmark Average Market Cap	Rs 14,150.82 crore

Glenmark operates in Healthcare and specifically in Pharmaceuticals & Drugs. The industry benchmark covers 201 companies, so the comparison is broad enough to show whether the stock sits near the middle of the pack or stands out on size, valuation and returns.

On valuation, Glenmark’s P/E of 38.89 is above the industry median of 32.19 but below the average of 49.13. Its P/B of 6.38 is above both the median of 3.05 and the average of 4.44. On profitability, the picture is stronger: ROE of 14.1% is above the median of 11.82% and average of 11.12%, while ROCE of 20.35% is above the median of 13.71% and average of 13.62%.

Size also matters in context. Glenmark’s market capitalisation of Rs 69,483.71 crore is far higher than the industry median of Rs 715.6 crore and the average of Rs 14,150.82 crore. Even so, it remains below the industry maximum of Rs 4,55,825.66 crore. Taken together, the benchmark data shows a company that is much larger than the typical listed pharma business, delivers better-than-average returns, and trades at a premium to median sector valuations.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,55,825.66	37.31	5.22	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,018.51	86.86	14.38	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,86,874.73	86.55	21.03	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,211.69	25.42	4.25	19.69	21.39
Cipla	CIPLA	1,12,773	33.17	3.18	11.83	16

Peer data places Glenmark between lower-multiple names and high-premium pharma stocks. It is smaller than each of the listed peers in the supplied set, but its returns are competitive in several cases.

Against Sun Pharmaceutical Industries, Glenmark’s P/E of 38.89 is slightly higher than 37.31, its ROE of 14.1% is a little lower than 14.85%, and its ROCE of 20.35% is higher than 19.11%. Compared with Divi’s Laboratories and Torrent Pharmaceuticals, Glenmark trades at much lower P/E multiples than 86.86 and 86.55, but also carries lower ROE than 16.19% and 26.76%.

Versus Zydus Lifesciences and Cipla, Glenmark has a higher P/E than 25.42 and 33.17. Its ROCE is above Cipla’s 16% and just below Zydus’ 21.39%. On price-to-book, Glenmark’s 6.38 is above Sun’s 5.22, Zydus’ 4.25 and Cipla’s 3.18, but below Divi’s 14.38 and Torrent’s 21.03. This puts the stock in an interesting middle zone: not as richly valued as the most expensive peers, but still carrying a premium over several large pharma companies.

Why Investors Are Watching Glenmark Pharmaceuticals

• The stock is down 2.56% today, from Rs 2,477.35 to Rs 2,414.
• It opened at Rs 2,486.9, which was also the day’s high, and then fell to Rs 2,403.1.
• Valuation remains in focus, with P/E at 38.89 and P/B at 6.38.
• Profitability is comparatively solid, with ROE of 14.1% and ROCE of 20.35%.
• Its scale is significant, with a market cap of Rs 69,483.71 crore in an industry benchmark set of 201 companies.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. In the supplied market snapshot, it is categorised as a Large Cap company. With a market capitalisation of Rs 69,483.71 crore, it stands far above the same-industry median company size and remains relevant to investors tracking established listed drug makers rather than smaller niche stocks.

Track Glenmark Pharmaceuticals Share Price on Univest

UseGlenmark Pharmaceuticals (GLENMARK) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, users can track price, market capitalisation, valuation ratios, peer comparison and broader sector context in one place. That helps put today’s fall into a wider framework rather than viewing the move in isolation.

Frequently Asked Questions

What happened to Glenmark Pharmaceuticals Share Price today?

Ans. Glenmark Pharmaceuticals Share Price fell 2.56% to Rs 2,414 from the previous close of Rs 2,477.35. The absolute day change was Rs 63.35 lower at the time of the captured snapshot.

Why is Glenmark Pharmaceuticals falling today?

Ans. The supplied data confirms the stock declined today, but it does not establish a company-specific catalyst. What is verified is the move from Rs 2,477.35 to Rs 2,414 and the weak intraday pattern after the open.

What do Glenmark Pharmaceuticals valuation ratios show?

Ans. The stock trades at a P/E ratio of 38.89 and a P/B ratio of 6.38. Both are above industry median levels in the supplied benchmark data. The relevant peer median P/E is 32.19x.

How does Glenmark Pharmaceuticals compare with major pharma peers?

Ans. Its P/E is higher than Sun Pharma, Zydus and Cipla, but lower than Divi’s Laboratories and Torrent Pharmaceuticals. Its ROCE is above Sun, Torrent and Cipla, but below Divi’s and Zydus.

What were the key trading levels for Glenmark Pharmaceuticals today?

Ans. The stock opened at Rs 2,486.9, which was also the day’s high, and later fell to a low of Rs 2,403.1. It was trading at Rs 2,414 at the captured update time.

What do EPS, book value and dividend yield indicate for Glenmark Pharmaceuticals?

Ans. EPS is Rs 63.7, book value is Rs 388.43 per share, and dividend yield is 0.1%. These metrics describe earnings per share, accounting net worth per share and historical payout yield respectively.

How does Glenmark Pharmaceuticals compare with the pharma industry benchmark?

Ans. In a same-industry set of 201 companies, its ROE and ROCE are above industry medians, while its P/E and P/B are also above median levels. That points to stronger returns alongside a valuation premium.

Where can investors track Glenmark Pharmaceuticals Share Price updates?

Ans. Investors can follow Glenmark Pharmaceuticals Share Price on Univest for live price updates, market cap, valuation ratios, peer comparison and sector context. The previous close was Rs 2,477.35. The stock moved 2.56% lower during the session.